Ruthenium-based complexes as anti-tumor agents
Open Access
- 30 August 2024
- journal article
- Published by University of Sarajevo Faculty of Health Sciences in Journal of Health Sciences
- Vol. 14 (2) , 70-83
Abstract
Extensive research into platinum-based chemotherapeutics has been underway for decades with ruthenium-based complexes emerging as interesting and potent candidates. Even still, there is no evidence of a single mechanism of action across all synthesized and tested Ru-based complexes, prompting the continuance of research in this field. In addition, the mechanism of action varies according to cell line and/or animal model and is seemingly highly individualized and personalized. In accordance with this, the ruthenium complexes are able to activate specific molecular pathways and interact with certain targets within the cell, sometimes reported simultaneously. In this review, we attempt to give a new perspective on ruthenium complexes’ anti-cancer properties and organize selected results from the past 15 years of research connecting their structure with the reported mechanism of action. These results corroborate the previously reported great potential that ruthenium complexes have on cancer in vitro. In addition, the review provides insight into Ru drugs in their clinical trials and their efficacy against cancer including a historical context on metallodrugs, particularly platinum-based complexes, and their antitumor capability.Keywords
This publication has 69 references indexed in Scilit:
- Ruthenium(II)‐Dithiocarbazates as Anticancer Agents: Synthesis, Solution Behavior, and Mitochondria‐Targeted Apoptotic Cell DeathChemistry – A European Journal, 2023
- Recent Advances in Schiff Base Ruthenium Metal Complexes: Synthesis and ApplicationsTopics in Current Chemistry, 2021
- In vitro evaluation of cytotoxicity and antimetastatic properties of novel arene ruthenium(II)‐tetrazolato compounds on human cancer cell linesApplied Organometallic Chemistry, 2021
- Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer CellsJournal of Gastrointestinal Cancer, 2019
- Designing luminescent ruthenium prodrug for precise cancer therapy and rapid clinical diagnosisBiomaterials, 2019
- Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cellsBiomaterials, 2017
- Ruthenation of Non‐stacked Guanines in DNA G‐Quadruplex Structures: Enhancement of c‐MYC ExpressionAngewandte Chemie International Edition, 2016
- Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides To Target Integrin Receptors in Cancer CellsEuropean Journal of Inorganic Chemistry, 2016
- A Dinuclear Ruthenium(II) Schiff Base Complex with Dissimilar Coordination: Synthesis, Characterization, and Biological ActivityZeitschrift für anorganische und allgemeine Chemie, 2016
- Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapyInvestigational New Drugs, 2014